Results 21 to 30 of about 49,931 (273)

Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review

Frontiers in Oncology, 2022
To investigate literature-based evidence regarding progression-free survival (PFS) as an early efficacy endpoint in patients with resectable esophageal or gastroesophageal junction (GEJ) cancer receiving neoadjuvant therapy, this study identified large ...
Jie Zhu, Jie Zhu, Jin Tao, Zhen Dai, Yan Tan, Yan Tan, Li Jiang, Li Jiang, Qifeng Wang, Qifeng Wang, Jinyi Lang, Jinyi Lang   +11 more
doaj   +1 more source

Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
Background Surrogate endpoint trials test strategies more efficiently but are accompanied by uncertainty about the relationship between changes in surrogate markers and clinical outcomes.
Behnood Bikdeli, Natdanai Punnanithinont, Yasir Akram, Ike Lee, Nihar R. Desai, Joseph S. Ross, Harlan M. Krumholz   +6 more
doaj   +1 more source

Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer

Cancer Reports, 2021
Background The purpose of this study was to investigate the correlation between overall survival (OS) and other clinical outcomes in patients with prostate cancer. Further, we conducted subgroup analysis in the correlation of OS.
Hideki Maeda, Kentaro Takeda, Hisashi Urushihara, Tatsuo Kurokawa   +3 more
doaj   +1 more source

Effect of estimating equations for glomerular filtration rate on novel surrogate markers for renal outcome [PDF]

Kidney Research and Clinical Practice, 2021
Backgrounds Recently, alternative surrogate endpoints such as a 30% or 40% decline in estimated glomerular filtration rate (eGFR) or eGFR slope over 2 to 3 years have been proposed for predicting renal outcomes.
Kipyo Kim, Eunji Baek, Suryeong Go, Hyung-Eun Son, Ji-Young Ryu, Yongjin Yi, Jong Cheol Jeong, Sejoong Kim, Ho Jun Chin   +8 more
doaj   +1 more source

Biomarkers and surrogate endpoints [PDF]

British Journal of Clinical Pharmacology, 2005
When David Beckham leaves the field towards the end of a match, the man who replaces him is a surrogate. and although I suspect that many footballers, if asked, would say that Surrogate is a town in Yorkshire, the word actually comes from the Latin word subrogare, to substitute.
openaire   +3 more sources

Scoping and targeted reviews to support development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: protocol

BMJ Open, 2022
Introduction Using a surrogate endpoint as a substitute for a primary patient-relevant outcome enables randomised controlled trials (RCTs) to be conducted more efficiently, that is, with shorter time, smaller sample size and lower cost. However, there is
Derek Stewart, Rod Taylor, Christopher Weir, Oriana Ciani, Philippa Davies, Anthony Muchai Manyara, Valerie Wells   +6 more
doaj   +1 more source

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialsResearch in context

EClinicalMedicine, 2023
Summary: Background: Interventional trials that evaluate treatment effects using surrogate endpoints have become increasingly common. This paper describes four linked empirical studies and the development of a framework for defining, interpreting and ...
Oriana Ciani, Anthony M. Manyara, Philippa Davies, Derek Stewart, Christopher J. Weir, Amber E. Young, Jane Blazeby, Nancy J. Butcher, Sylwia Bujkiewicz, An-Wen Chan, Dalia Dawoud, Martin Offringa, Mario Ouwens, Asbjørn Hróbjartssson, Alain Amstutz, Luca Bertolaccini, Vito Domenico Bruno, Declan Devane, Christina D.C.M. Faria, Peter B. Gilbert, Ray Harris, Marissa Lassere, Lucio Marinelli, Sarah Markham, John H. Powers, Yousef Rezaei, Laura Richert, Falk Schwendicke, Larisa G. Tereshchenko, Achilles Thoma, Alparslan Turan, Andrew Worrall, Robin Christensen, Gary S. Collins, Joseph S. Ross, Rod S. Taylor   +35 more
doaj   +1 more source

Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China

Frontiers in Public Health, 2022
ObjectiveThis study aimed to assess whether different clinical trial endpoints in pivotal trials of cancer drugs were associated with reimbursement decisions in China.Materials and methodsCancer drugs marketed before June 30th, 2021 with publicly ...
Kexin Ling, Huli Qin, Yiman Feng, Hongxi Che, Jinxi Ding, Jinxi Ding, Wei Li, Wei Li   +7 more
doaj   +1 more source

Bivariate network meta-analysis for surrogate endpoint evaluation [PDF]

, 2019
Surrogate endpoints are very important in regulatory decision making in healthcare, in particular if they can be measured early compared to the long-term final clinical outcome and act as good predictors of clinical benefit.
Sylwia Bujkiewicz, Bujkiewicz, S, R Turner (7767329), Nicolas Städler, White, IR, S Bujkiewicz (7657214), N Steadler (7767332), J Thompson (7706261), Rebecca M. Turner, Ian R. White, John R. Thompson, Abrams, KR, K Abrams (7660040), I White (7714724), Keith R. Abrams, Jackson, D, Thompson, JR, Dan Jackson, Turner, RM, Städler, N, D Jackson (5851175)   +20 more
core   +4 more sources

Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition

Journal of Causal Inference, 2015
A common problem of interest within a randomized clinical trial is the evaluation of an inexpensive response endpoint as a valid surrogate endpoint for a clinical endpoint, where a chief purpose of a valid surrogate is to provide a way to make correct ...
Gilbert Peter B., Gabriel Erin E., Huang Ying, Chan Ivan S.F.   +3 more
doaj   +1 more source